Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €46.26 EUR
Change Today +1.32 / 2.93%
Volume 0.0
NK8 On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 2:06 AM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

nuvasive inc (NK8) Snapshot

Open
€46.26
Previous Close
€44.94
Day High
€46.26
Day Low
€46.26
52 Week High
05/29/15 - €46.51
52 Week Low
07/29/14 - €25.86
Market Cap
2.3B
Average Volume 10 Days
5.5
EPS TTM
--
Shares Outstanding
48.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NUVASIVE INC (NK8)

nuvasive inc (NK8) Related Businessweek News

No Related Businessweek News Found

nuvasive inc (NK8) Details

NuVasive, Inc., a medical device company, develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for the spine. Its products focus on applications for spine fusion surgery. The company’s principal product is Maximum Access Surgery (MAS), a minimally-disruptive surgical platform that includes its proprietary software-driven nerve detection and avoidance systems, NVM5 and NVJJB, and intra-operative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics. Its spine surgery product line offerings comprise products for the thoracolumbar and the cervical spine, which are primarily used to enable surgeons access to the spine and to perform restorative and fusion procedures in a minimally disruptive fashion. The company’s biologic product line offerings used to aid the spinal fusion process or bone healing process consist of Osteocel Plus and Osteocel Pro allograft (donated human tissue), which are cellular matrix products containing viable mesenchymal stem cells; FormaGraft, a collagen synthetic product; and AttraX, a synthetic bone graft material. It also provides IOM services for insight into the nervous system during non-spine. The company sells its products through independent sales agencies, directly-employed sales shareowners to surgeons and hospitals in the United States and internationally. NuVasive, Inc. was founded in 1997 and is headquartered in San Diego, California.

1,500 Employees
Last Reported Date: 02/25/15
Founded in 1997

nuvasive inc (NK8) Top Compensated Officers

President and Chief Operating Officer
Total Annual Compensation: $545.7K
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $380.5K
President of U.S. Commercial
Total Annual Compensation: $375.0K
Executive Vice President of International and...
Total Annual Compensation: $454.1K
Consultant
Total Annual Compensation: $900.0K
Compensation as of Fiscal Year 2014.

nuvasive inc (NK8) Key Developments

NuVasive, Inc. Announces Executive Appointments

NuVasive, Inc. appointed Pat Miles as president and COO, and Matt Link as president for US commercial. Mr. Miles has been with NuVasive for 14 years. Most recently, he has overseen the launch of Integrated Global Alignment, or iGA. Mr. Link joined NuVasive in 2006 and has been a key leader in NuVasive's unmatched sales growth over that period of time. Mr. Link most recently served as the company's President, US Sales and Service.

NuVasive, Inc. Appoints Jason Hannon as Executive Vice President, International

NuVasive Inc. announced the appointment of Jason Hannon as Executive Vice President, International. In his new role, he will be responsible for the company's business and commercial operations outside of the United States. Hannon will be relocating to NuVasive's International headquarters in Amsterdam, the Netherlands where he will drive the Company's international expansion strategy. Hannon will continue to serve as NuVasive's General Counsel until a successor is identified, for which an active search is underway.

NuVasive, Inc. Announces Executive Changes

Effective as of July 9, 2015, the Board of Directors of, Inc. accepted the resignation of Dr. Peter Leddy, Ph.D. as a director. Dr. Leddy resigned from the Board in connection with his appointment as the company's Executive Vice President, Human Resources and Corporate Integrity. In this new role, Dr. Leddy will serve as an executive officer of the company with leadership responsibilities for the company's human resources, compliance, regulatory and facilities functions. On July 13, 2015, the company appointment Dr. Leddy as Executive Vice President, Human Resources and Corporate Integrity, as well as other additions and changes in roles and responsibilities of the company's executive leadership team. NuVasive’s executive leadership team, reporting directly to Mr. Lucier, includes: Jason Hannon, Executive Vice President, International and General Counsel: Mr.Hannon assumes the role of Executive Vice President, International from Russell Powers, who continues to serve as an Executive Vice President and a member of the executive leadership team at NuVasive and will focus on NuVasive’s expansion into greater China. Mr. Hannon has extensive experience at NuVasive in the areas of corporate development, mergers and acquisitions, and regulatory and legal. In his new role, Mr. Hannon will be responsible for NuVasive’s business and commercial operations outside of the United States, including leading the company’s international expansion opportunities. Carol Cox, Executive Vice President, Strategy, Corporate Development and External Affairs: Ms. Cox assumes the role of Executive Vice President, Strategy, Corporate Development and External Affairs. Ms. Cox has more than 20 years of senior level experience in cross-functional corporate roles in the healthcare sector. She joined the company in 2014, most recently serving as Executive Vice President of Corporate Affairs and Human Resources. In her new role, Ms. Cox will be responsible for leading NuVasive’s corporate development and mergers and acquisitions strategy, leveraging communications, investor relations and government affairs channels in support of the company’s strategic priorities, and creating a corporate marketing and brand team. Pete Leddy, Ph.D, Executive Vice President, Human Resources and Corporate Integrity: Dr. Leddy assumes leadership of the company’s human resources, compliance, regulatory and facilities functions after serving as a member of NuVasive’s Board of Directors since 2011. In addition, NuVasive has begun a search for a Chief Information Officer, a newly created role, and a new General Counsel to replace Mr. Hannon, both of whom would also be part of the executive leadership team and report to Mr. Lucier.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NK8:GR €46.26 EUR +1.32

NK8 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CONMED Corp $57.73 USD +0.41
Cyberonics Inc $60.96 USD +0.46
Globus Medical Inc $27.29 USD +0.13
Integra LifeSciences Holdings Corp $64.69 USD -0.25
Masimo Corp $40.67 USD -0.42
View Industry Companies
 

Industry Analysis

NK8

Industry Average

Valuation NK8 Industry Range
Price/Earnings 72.2x
Price/Sales 3.1x
Price/Book 3.7x
Price/Cash Flow 52.5x
TEV/Sales 2.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NUVASIVE INC, please visit www.nuvasive.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.